Eli Lilly to acquire Ventyx Biosciences; will significantly strengthen immunology and neurology portfolio | iPharmaCenter
Eli Lilly has entered a definitive agreement to acquire Ventyx Biosciences in an all‑cash transaction valued at approximately 1.2 billion dollars, aiming to strengthen its position in orally delivered therapies for chronic, inflammation‑mediated diseases. Ventyx contributes a differentiated portfolio of small‑molecule oral candidates targeting autoimmune, inflammatory and neurodegenerative diseases, centered on NLRP3 inhibition and advanced IBD assets. Deal overview Lilly wil
China Grants Approval to Nucala for COPD Management | iPharmaCenter
China’s National Medical Products Administration has officially cleared Nucala (mepolizumab) as a supplemental maintenance therapy for adults suffering from chronic obstructive pulmonary disease (COPD). This authorization specifically targets patients whose condition remains poorly managed and is linked to elevated levels of eosinophils in the blood. Nucala: A Milestone in Biological Respiratory Care Nucala stands as the inaugural monthly biological treatment in China indic
Japan approves GSK's Exdensur for asthma and chronic rhinosinusitis with nasal polyps
Japan has officially sanctioned Exdensur (depemokimab) as a pioneering, ultra-long-lasting biological therapy. This medication is now available for individuals struggling with intense bronchial asthma or chronic rhinosinusitis accompanied by nasal polyps (CRSwNP) who haven't found relief through traditional medical approaches. What distinguishes Exdensur from existing options? Developed by GSK, Exdensur biologic targets type 2 inflammation by binding to interleukin-5 (IL-5) w
Enhertu approved in China for HER2‑low or HER2‑ultralow metastatic breast cancer | iPharmaCenter
Enhertu (trastuzumab deruxtecan) has received marketing authorization in China as the first HER2‑targeting therapy for people with HER2‑low or HER2‑ultralow metastatic breast cancer whose disease has worsened after at least one endocrine treatment in the metastatic setting. The decision is supported by phase 3 DESTINY‑Breast06 data showing clinically meaningful improvements in progression‑free survival versus standard chemotherapy. New indication in China The National Medic
European Commission grants approval to Sanofi's Wayrilz for refractory immune thrombocytopenia | iPharmaCenter
European Commission grants approval to Sanofi's Wayrilz (rilzabrutinib), marking the first Bruton's tyrosine kinase (BTK) inhibitor for adult patients with refractory immune thrombocytopenia (ITP). Wayrilz, an oral and reversible BTK inhibitor, targets immune pathways through multi-immune modulation to tackle ITP's root causes, such as low platelet counts, bleeding risks, and quality-of-life burdens from this rare autoimmune disorder. The approval follows a positive CHMP opin
Boehringer Ingelheim Bolsters Pulmonary Fibrosis Portfolio with Jascayd Approval for Progressive Cases
Boehringer Ingelheim announced US Food and Drug Administration clearance for Jascayd (nerandomilast) tablets to treat progressive pulmonary fibrosis in adults. This marks the second indication for the therapy, following its recent approval for idiopathic pulmonary fibrosis. Jascayd introduces the first selective phosphodiesterase 4B inhibitor with both immune-modulating and anti-scarring properties approved for this serious lung disorder. FIBRONEER-ILD Trial Supports Approv